Sun Pharma

Sun Pharma Organon Acquisition: A $11.75 Billion Move to Lead Global Women’s Health

By BiotechReality Business Intelligence Desk
27 April 2026

Sun Pharmaceutical Industries has announced a definitive agreement to acquire Organon & Co. for $11.75 billion, marking a major expansion into women’s health and biosimilars.

Tag: Sun Pharma

Sun Pharma Organon Acquisition: A $11.75 Billion Move to Lead Global Women’s Health

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement